- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.08. | Morgan Stanley stuft Erasca-Aktie wegen verzögerter Studiendaten herab | 1 | Investing.com Deutsch | ||
| 18.08. | Morgan Stanley downgrades Erasca stock to Equalweight on delayed clinical data | 1 | Investing.com | ||
| 12.08. | Erasca files $500M mixed securities shelf | 2 | Seeking Alpha | ||
| ERASCA Aktie jetzt für 0€ handeln | |||||
| 12.08. | Erasca, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | Erasca, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Erasca, Inc.: Erasca Reports Second Quarter 2025 Business Updates and Financial Results | 157 | GlobeNewswire (Europe) | Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust balance... ► Artikel lesen | |
| 26.06. | Erasca, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.06. | Erasca Announces Clearance Of IND Application By FDA For ERAS-4001 | - | RTTNews | ||
| 02.06. | FDA clears Erasca's new cancer drug applications | 1 | Investing.com | ||
| 13.05. | Erasca, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 13.05. | Erasca, Inc.: Erasca Reports First Quarter 2025 Business Updates and Financial Results | 96 | GlobeNewswire (Europe) | Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026... ► Artikel lesen | |
| 13.05. | Erasca, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Erasca enters another era, seeks partner for ph. 3 ex-Novartis asset | 1 | FierceBiotech | ||
| 13.05. | FDA clears Erasca's new cancer drug ERAS-0015 | 1 | Investing.com | ||
| 29.04. | Erasca, Inc.: Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 26.03. | Raymond James sets $5 target for Erasca stock, cites valuation gap | 5 | Investing.com | ||
| 25.03. | Erasca, Inc.: Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 20.03. | Erasca GAAP EPS of -$0.11 beats by $0.02 | 3 | Seeking Alpha | ||
| 20.03. | Erasca, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 20.03. | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results | 587 | GlobeNewswire (Europe) | Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 85,65 | +0,06 % | Paukenschlag beim Übernahmekandidaten! 100 %-Aktie BioNxt Solutions lässt BioNTech und Co. hinter sich! | Die Aktie von BioNxt ist endlich angesprungen. Anfang Juli hatten wir zuletzt auf die Chancen des kanadisch-deutschen Biowissenschaftsunternehmens hingewiesen. Seitdem ist die Aktie um fast 100 % gestiegen... ► Artikel lesen | |
| CUREVAC | 4,618 | +0,70 % | CureVac mit EILMELDUNG: Könnte die Aktie am Montag komplett einbrechen - Experten warnen!!! | ||
| MODERNA | 20,610 | +0,12 % | Moderna, Inc.: Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2 | CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications... ► Artikel lesen | |
| PAION | 0,013 | -50,00 % | Paion Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| NOVAVAX | 6,377 | -0,20 % | H.C. Wainwright startet Coverage für Novavax mit "Buy"-Rating und Kursziel von 10 US-Dollar | ||
| NANOREPRO | 1,915 | +0,52 % | HV-Termine: Hauptversammlungen u.a. bei Baywa, Circus, Daldrup, Laiqon, NanoRepro, Pyramid, Umweltbank | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| 4SC | 0,708 | -1,12 % | PTA-News: 4SC AG: 4SC veröffentlicht Halbjahresbericht 2025 | DJ PTA-News: 4SC AG: 4SC veröffentlicht Halbjahresbericht 2025
Unternehmensmitteilung für den Kapitalmarkt
4SC AG: 4SC veröffentlicht Halbjahresbericht 2025
Planegg-Martinsried (pta000/08.08.2025/07:30... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| INOVIO PHARMACEUTICALS | 1,980 | -1,98 % | INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug | ||
| INFLARX | 1,364 | +0,66 % | InflaRx N.V.: InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update | INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson BioPharmaceuticals... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,504 | +3,28 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Debenture Units Financing | Montreal, Quebec--(Newsfile Corp. - August 22, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in drug... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,144 | +0,62 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Departure of Dr. Helen Thackray | RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will... ► Artikel lesen | |
| DYNAVAX | 9,048 | +4,65 % | Dynavax Technologies: Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile | At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolerated and demonstrated a favorable tolerability profile, including lower solicited... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,320 | -1,49 % | RedHill Biopharma Ltd.: RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease | The positive FDA feedback allows for:
A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium... ► Artikel lesen |
ERASCA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,32 % bei einem Aktienkurs von 1,575 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ERASCA INC finden Sie auf Wallstreet Online.